-DOCSTART- -X- O
We -X- _ O
randomized -X- _ O
115 -X- _ B-Patient
children -X- _ I-Patient
to -X- _ O
trivalent -X- _ B-Intervention
inactivated -X- _ I-Intervention
influenza -X- _ I-Intervention
vaccine -X- _ I-Intervention
( -X- _ I-Intervention
TIV -X- _ I-Intervention
) -X- _ I-Intervention
or -X- _ O
placebo. -X- _ B-Comparison
Over -X- _ O
the -X- _ O
following -X- _ O
9 -X- _ O
months -X- _ O
, -X- _ O
TIV -X- _ B-Outcome
recipients -X- _ I-Outcome
had -X- _ I-Outcome
an -X- _ I-Outcome
increased -X- _ I-Outcome
risk -X- _ I-Outcome
of -X- _ I-Outcome
virologically-confirmed -X- _ I-Outcome
non-influenza -X- _ I-Outcome
infections -X- _ I-Outcome
( -X- _ I-Outcome
relative -X- _ I-Outcome
risk -X- _ I-Outcome
: -X- _ I-Outcome
4.40 -X- _ I-Outcome
; -X- _ I-Outcome
95 -X- _ I-Outcome
% -X- _ I-Outcome
confidence -X- _ I-Outcome
interval -X- _ I-Outcome
: -X- _ I-Outcome
1.31-14.8 -X- _ I-Outcome
) -X- _ I-Outcome
. -X- _ I-Outcome
Being -X- _ I-Outcome
protected -X- _ I-Outcome
against -X- _ I-Outcome
influenza -X- _ I-Outcome
, -X- _ I-Outcome
TIV -X- _ I-Outcome
recipients -X- _ I-Outcome
may -X- _ I-Outcome
lack -X- _ I-Outcome
temporary -X- _ I-Outcome
non-specific -X- _ I-Outcome
immunity -X- _ I-Outcome
that -X- _ I-Outcome
protected -X- _ I-Outcome
against -X- _ I-Outcome
other -X- _ I-Outcome
respiratory -X- _ I-Outcome
viruses -X- _ I-Outcome
. -X- _ O

